PCI Biotech Holding Overview
- Year Founded
-
2000
- Status
-
Public
- Employees
-
7
- Stock Symbol
-
PCIB
- Share Price
-
$0.14
- (As of Friday Closing)
PCI Biotech Holding General Information
Description
PCI Biotech Holding ASA is a biopharmaceutical company. It focuses on developing and commercializing therapies for the treatment of cancer through its photochemical internalization (PCI) technology platform. The PCI technology works by inducing light-triggered endosomal release. PCI is applied to three distinct anticancer paradigms; fimaCHEM which is an enhancement of chemotherapeutics for localized treatment of cancer, fimaVACC which is T-cell induction technology for therapeutic vaccination, and fimaNAc which is nucleic acid therapeutics delivery. Its therapeutic product candidate is the photosensitizer fimaporfin (Amphinex) which can unlock the intracellular capsules where active compounds are trapped.
Contact Information
- Ullernchauséen 64
- 0379 Oslo
- Norway
PCI Biotech Holding Stock Performance
(As of Friday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $0.14 | $0.14 | $0.13 - $0.60 | $5.31M | 37.3M | 149K | -$0.08 |
PCI Biotech Holding Financials Summary
|
In Thousands, USD |
TTM 30-Jun-2023 | FY 2022 31-Dec-2022 | FY 2021 31-Dec-2021 | FY 2020 31-Dec-2020 |
|---|---|---|---|---|
| EV | 2,438 | 1,569 | 43,642 | 99,734 |
| Revenue | 0 | 0 | 0 | 0 |
| EBITDA | (2,903) | (5,153) | (10,019) | (7,554) |
| Net Income | (2,828) | (5,701) | (10,249) | (7,634) |
| Total Assets | 4,860 | 6,477 | 15,415 | 24,497 |
| Total Debt | 53 | 79 | 216 | 79 |
PCI Biotech Holding Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
PCI Biotech Holding Executive Team (6)
| Name | Title | Board Seat | Contact Info |
|---|---|---|---|
| Ronny Skuggedal | Chief Executive Officer | ||
| Anders Høgset Ph.D | Chief Scientific Officer & Research Director | ||
| Ludovic Robin | Chief Business Officer |
PCI Biotech Holding Board Members (9)
| Name | Representing | Role | Since |
|---|---|---|---|
| Hans Bøhn MD | PCI Biotech Holding | Chairman of the Board | 000 0000 |
| Hilde Steineger Ph.D | Self | Board Member | 000 0000 |
| Kjetil Taskén Ph.D | Self | Board Member | 000 0000 |
PCI Biotech Holding Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Twitter Followers
5.5k
Similarweb Unique Visitors
15.0K
Majestic Referring Domains
314
PCI Biotech Holding Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
PCI Biotech Holding ESG
Risk Overview
Risk Rating
Updated December, 07, 2021
31.84 | High Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
00.0
Management
Management is related to actions taken to manage ESG issues
00.00
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
00 of 14,860
Rank
Percentile
Pharmaceuticals
Industry
00 of 964
Rank
Percentile
Biotechnology
Subindustry
00 of 441
Rank
Percentile
